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correlations between the slope, D5 v, D2 v, HRCTV D90, 
HRCTV volume, and the RV point. 
 
Results: Total doses from 3 fractions for the D5 v median 
48.7Gy (range 31.4 - 76.6Gy), D2 v median 64.0Gy (range: 
43.2 - 112Gy) and RV median dose 16.3Gy (range: 11.6 – 
25.3Gy) The RV point exhibited a weak correlation with D2 v 
(r=0.56; p=0.0001) and D5 v (r = 0.55; p=0.0001) respectively. 
A moderate correlation was observed between the HRCTV 
volume and the D2 v (r = 0.69; p=0.0001), the HRCTV volume 
and D5 v (r = 0.73; p=0.0001) and a weak correlation with the 
HRCTV volume and the RV Point (r=0.57; p=0.0001). The 
slope correlated with D2 v (r= -0.96; p=0.0001) and D5 v (r=-
0.87; p=0.0001) and a weak correlation with the RV point (r=-
0.52; p=0.0002). No correlation was found between the 
HRCTV D90 and the D2v (r=-0.20; p=0.1826), the D5v (r=-
0.24; p=0.1082), or the RV Point (r=0.02; p=0.8431). 
 
Conclusion: The expansion volume of the ring applicator cap 
can provide a suitable surrogate for determining the vaginal 
mucosa dose, as this part of the vagina is in close proximity 
to the ring and tandem contributing to the volume of vaginal 
mucosa receiving the highest vaginal dose. The RV point does 
not correlate with the D2v and D5v and therefore can not to 
be use as a suitable surrogate point for the dose to the 
vaginal mucosa. Additional work is currently ongoing to 
correlate the D2v and D5v with clinically measured vaginal 
morbidity. 
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Purpose or Objective: In order to evaluate the usefulness of 
high-dose-rate image-guided interstitial brachytherapy (HDR-
ISBT) for recurrent uterine cervical adenocarcinoma, we 
analyzed our clinical experience. 
 
Material and Methods: We investigated 28 patients treated 
with HDR-ISBT at National Hospital Organization Osaka 
National Hospital between May 2003 and December 2010. All 
patients received radical surgery and 7 patients also received 
post-operative radiotherapy as previous treatments. 
Histologic finding was adenocarcinoma and squamous cell 
carcinoma for 11 and 17 patients. In 11 adenocarcinoma 
patients, 6 patients had endometrioid adenocarcinoma and 
the other 5 patients had mucinous adenocarcinoma. The 
median tumor size was 23 mm (range; 5-79 mm). In 21 
patients who had no irradiation history, 9 patients were 
treated with HDR-ISBT alone and the other 12 patients were 
treated with HDR-ISBT plus external beam radiotherapy 
(EBRT). Forty-eight to 54 Gy in 8 to 9 fractions were 
delivered as monotherapy and 30 to 33 Gy in 5 to 6 fractions 
as combination of EBRT. In 7 patients who had irradiation 
history, slight lower doses (42 to 48 Gy in 7 to 8 fractions) 
were selected. We implanted 7–15 (median, 12) applicators 
under transrectal ultrasonography guidance. We used free-
hand implantation with ambulatory technique for later 25 
patients. Magnetic resonance imaging (MRI)-assisted image-
based treatment planning was performed for later 17 
patients. Clinical target volumes (CTV) were the gloss tumor 
volume with or without 10 mm of vaginal margin for patients 
with or without non-irradiation history. 
 
Results: The median follow-up time was 43 months (range; 4-
115 months). The median D90(CTV)s were 120%prescribed 
dose (PD), 122%PD and 118%PD for patients who had 
endometrioid adenocarcinoma, mucinous adenocarcinoma 
and squamous cell carcinoma. The 3-year local control and 
overall survival rates were 72% and 73% for adenocarcinoma. 
The 3-year local control and overall survival rates were 88% 
and 77% for squamous cell carcinoma. No significant 
difference was observed. The 3-year local control rates were 
both 67% for endometrioid adenocarcinoma and mucinous 
adenocarcinoma. Grade 3-4 late complications occurred by 
HDR-ISBT in 5 patients (18%). 
 
Conclusion: Our treatment result of image-based HDR-ISBT 
showed that slight inferior result was observed in cervical 
adenocarcinoma although there was no significant difference. 
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Purpose or Objective: Brachytherapy is one the most 
important components in the treatment of cervical cancer. 
Recently 3D planning for brachytherapy has been used which 
could be done both by CT and MRI imaging based. We 
compared the high risk clinical target volumes contoured on 
CT and MRI and dose distribution in the target volumes and 
organs at risk. 
 
Material and Methods: Twenty three patients with IIA-IIIB 
stage cervical cancer were planned for HDR brachytherapy 
with ring-tandem applicators. Treatment consisted of four 7 
Gy fractions by two insertion procedures. On MRI and CT sets 
we contoured HR CTV and organs at risk on 42 plans: for 19 
patients two plans and for four patients only one. Medical 
physicists received task to make planning on CT and MRI 
images independently at the same day before irradiation. 
The mean HR CTV volume, dose received by at least 90% of 
the volume (D90) and the dose to 2 cc for the organs at risk 
were evaluated. 
 
Results: The mean volume of HR CTV was 77.5 cc on CT 
based contours and 60.3 cc on MRI imaging. This difference in 
HR CTV volume reflected on the dose to organs at risk – 
physicists have to increase it to achieve prescribed dose in 
target volume. Thus, while assessing mean D2cc for rectum, 
bladder and sigmoid we find out that it was lower in case of 
MRI based planning compare to CT based planning – 66.2 Gy 
and 70.3 Gy, 85.1 Gy and 89.6 Gy, 62.3 Gy and 66.7 Gy 
respectively. Mean D90 also was significantly higher in MRI 
compared to CT imaging plans – 94,2% versus 79,4% of 
prescribed dose. 
 
Conclusion: In spite that superiority of MRI compared to CT 
imaging based contouring and planning for HR CTV dose 
distribution has been already showed in previous studies we 
found that it also allows indirectly significantly decrease the 
dose to organs at risk during HDR brachytherapy for cervical 
cancer. 
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Purpose or Objective: To retrospectively assess treatment 
outcome of image guided brachytherapy (IGBT) with or 
without hybrid technique for cervical cancer using 
VariSourceTM titanium ring applicator with ‘Siriraj Ring Cap’ 
extension (as figure 1). In case of narrow vaginal opening, 
hybrid brachytherapy technique could be performed using 
this applicator with extension. 
Figure 1: VariSourceTM titanium ring applicator with ‘Siriraj 
Ring Cap’ extension 
